Scinopharm Taiwan Ltd.

TAINAN, Taiwan, February 8, 2011 - ScinoPharm, a leading active pharmaceutical ingredient (API) and contract research and manufacturing (CRAM) service provider to the global pharmaceutical and biotechnology industry, will provide commercial manufacturing service of vilazodone hydrochloride active pharmaceutical ingredient (API) for Clinical Data, Inc.'s Viibryd(TM), a new drug entity recently approved by the United States Food and Drug Administration.

TAINAN, Taiwan, August 31, 2010 - ScinoPharm, a leading active pharmaceutical ingredient (API) developer and manufacturer headquartered in Taiwan, today announced an investment into Tanvex Biologics, Inc., a United States company registered in the State of Delaware.